Kornimate/medical-research-clean huggingface dataset:
dehydroepiandrosterone administration in women with systemic lupus erythematosus or primary sjögren's syndrome

Conditions: Lupus Erythematosus, Systemic; Sjogren's Syndrome

Summary: the purpose of the study is to examine whether dehydroepiandrosterone (dhea) administration improves fatigue and general well-being in patients with systemic lupus erythematosus or primary sjögren's syndrome

fatigue and reduced general well-being are frequent complaints in patients with the chronic autoimmune disorder systemic lupus erythematosus (sle) or primary sjögren's syndrome (pss). uncontrolled studies suggested that the administration of dehydroepiandrosterone (dhea) may improve such complaints. the aim of our randomized double-blind placebo-controlled study is to examine the effect of daily oral 200 mg dhea on fatigue, well-being, and functioning in women with sle or pss.

Eligibility criteria:
inclusion criteria: * pss with a focus score \>= 1 on minor salivary gland biopsy and fulfilling european classification criteria (ann rheum dis 1996;55:116-21) * sle according to acr classification criteria (arthritis rheum 1982;25:1271-7) * willingness to apply effective contraception (premenopausal women) * written informed consent. exclusion criteria: * pregnancy * pregnancy wish * serum creatinine \> 150 µmol/l * glucocorticoid use at a daily dose \> 10 mg prednisone (or equivalent) * cyclophosphamide treatment in the preceding year * hyper- or hypothyroidism * history of malignancy within the previous 5 years with exception of squamous or basal cell carcinoma of the skin

Keywords: dehydroepiandrosterone fatigue quality of life lupus erythematosus, systemic sjogren's syndrome bone mineral density
a four week study of azithromycin ophthalmic solution, 1% versus rewetting drops in subjects with history and current complaint of contact lens-related dry eye (clde)

Conditions: Contact Lens Dry Eye

Summary: the primary objective of this study is to compare the duration of subject reported comfortable contact lens daily wear time in subjects with a history and current complaint of clde during a 29-day treatment period of azithromycin ophthalmic solution, 1%, compared to rewetting drops


Eligibility criteria:
inclusion criteria: * have a history of and current complaint of clde. * use properly fitted daily-wear soft contact lenses. * able to wear contact lenses for at least 8 hours a day. * if female, are non-pregnant or non-lactating. exclusion criteria: * have changed brand of contact lens or care solutions within one month prior to visit 1. * use extended (overnight) wear contact lenses. * have a clinically significant ophthalmic abnormality. * have had cauterization of the punctum or have had punctal plugs (silicone or collagen) inserted or removed within the 90 days prior to the screening. * have any active ongoing ocular infection or ocular disease. * have a serious medical condition which could confound study assessments.
clinical outcomes of immediate implant placement and early implant placement

Conditions: Tooth Fractures; Tooth Diseases

Summary: immediate implant placement (iip) has been an attractive treatment concept for both patients and clinicians due to reduced surgical interventions and total treatment span. although soft-tissue alterations or midfacial recession have been demonstrated in previous studies, recent studies have reported positive result following iip with the modification of surgical interventions. however, high-quality evidence (≥ib: evidence from at least one randomized controlled trial) on comparing the clinical outcome of iip with early implant placement (type 2) is limited.


Eligibility criteria:
inclusion criteria: * age ≧18 years * single hopeless teeth in anterior maxilla * enough apical bone volume to achieve primary stability (\>4mm) exclusion criteria: * active periodontoal infection * incomplete buccal bone plate * unwilling to participate
a comparative study of cci, emsfi, and ftrst scoring systems

Conditions: One Hundred Patients Aged 65 and Older Who Underwent Emergency General Surgical Interventions; Clinical Utility of These Scoring Systems

Summary: frailty assessment tools and comorbidity indices play a crucial role, particularly in predicting outcomes for elderly patients undergoing emergency surgery. the emergency surgery frailty index (emsfi), charlson comorbidity index (cci), and the flemish version of the triage risk screening tool (ftrst) are considered valuable tools that help understand patients perioperative risk profiles. this study aims to investigate the accuracy and clinical utility of these scoring systems in predicting mortality in individuals aged 65 and older undergoing emergency surgery


Eligibility criteria:
inclusion criteria patients aged 65 years and older who underwent emergency abdominal surgery exclusion criteria: * multiple hospitalizations for the same pathology, * initial admission at another facility, * history of emergency abdominal surgery before the study period, * terminal-stage cancer * emergency reoperations following elective surgery, * surgery while in the intensive care unit.
the factors affecting ipp in peritoneal dialysis patients with polycystic kidney disease

Conditions: Peritoneal Dialysis; Polycystic Kidney Diseases

Summary: background: polycystic kidney disease (pkd) is the most common hereditary kidney disease. peritoneal dialysis (pd) in such patients is restricted because the significantly enlarged kidneys and liver may lead to the increase of intraperitoneal pressure (ipp). increased ipp points to higher risk of abdominal wall complications and limited infusion volume that cause insufficient dialysis adequacy. therefore, monitoring ipp is especially important in patients with polycystic kidney disease. however, the standard measurement of ipp is limited due to its cumbersome procedures, the application value of equation for estimating ipp among general peritoneal dialysis patients is not clear in the pkd population and the variables influence the ipp is yet to be explored.. objective: the main purpose of our study was to validate the existing ipp equations in the pkd patients. further, more relevant variables were included to optimize the ipp equation. monitoring ipp can guide the formulation of peritoneal dialysis prescription for adpkd patients, reduce the occurrence of abdominal wall complications, and the clinical utility and efficiency of pd was expanded. methods: a multi-center cross-sectional study. the ipps were measured using the durand method, with whole-body and abdominal anthropometry indices, the volume of abdominal cavity, the total kidney volume and liver volume were collected. new equation for estimate ipp in pkd patients were generated by stepwise linear regression modeling. the eipp were calculated using two developed equations previously. then the bias, accuracy and precision of eipp derived from new equation were compared with actual ipp by durand method respectively.


Eligibility criteria:
inclusion criteria: 1. aged 18-80 years; 2. a confirmed diagnosis of polycystic kidney disease, with a history of peritoneal dialysis catheter placement and regular peritoneal dialysis; 3. able to tolerate the infusion of more than 1500 ml of dialysis fluid. exclusion criteria: 1. acute complications such as peritonitis or cardiovascular and cerebrovascular events within the past month; 2. history of abdominal surgery or trauma within the past month; 3. history of kidney cyst rupture, infection, or bleeding within the past month; 4. history of abdominal or pelvic organ tumors; 5. history of abdominal pressure-related complications, such as hernias, leaks, or chest-abdominal fistulas; 6. unable to attend follow-up visits during the study period; 7. refusal to participate in the study. -
yoga and pilates based respiratory training effect for individuals with urinary incontinence

Conditions: Urinary Incontinence

Summary: the aim of the study is to examine and compare the effects of yoga-based and pilates-based respiratory training on incontinence severity, pelvic floor muscle function and quality of life in the rehabilitation of individuals with urinary incontinence.

in the literature, it has been stated that the pelvic floor alone does not play a singular role in maintaining continence, but rather forms a functional unit with the diaphragm, abdominal, and spinal muscles. since the inability of any of these structures to perform their function properly negatively affects the function of the others, normalization and optimal functioning of the pelvic floor-thoracic diaphragm relationship are crucial in individuals with urinary incontinence. this study aims to investigate the effectiveness of yoga and pilates approaches, considering breath as a fundamental building block, through respiration-based training programs in women with urinary incontinence. the participants who volunteered to take part in the study will be randomly divided into two groups, namely the yoga-based respiration group (group 1) and the pilates-based respiration group (group 2), using a computer-assisted randomization program. after the groups are assigned, the initial three sessions for both groups will be conducted face-to-face under the guidance of a physiotherapist to ensure the correct execution of the exercises. the exercise program for both groups will consist of approximately 20-minute sessions, with two sessions per day, five days a week, for a total of six weeks. on the days when face-to-face sessions are held, one session will be conducted in-person, while the other session will be performed at home. during the 3rd and 5th weeks, the exercises will be progressively intensified for both groups to ensure progression, and patients will be called for face-to-face sessions. at the end of the six weeks, patients will undergo face-to-face evaluations once again.

Eligibility criteria:
inclusion criteria: * having the diagnosis of stress or mixed urinary incontinence. * being volunteer to participate in the study. * having planned routine treatment program and being compliant with treatment * having no obstacles for the planned assessments. * people who capable of written, verbal and visual communication exclusion criteria: * having received treatment for urinary incontinence in the last 3 months. * using medication for vaginal or urinary tract infections. * pregnancy. * being within the first 3 years postpartum. * presence of concurrent pulmonary, neurological, rheumatological, or musculoskeletal disorders affecting spinal alignment. * history of surgery that may impede the exercise planned within the scope of the study.

Keywords: urinary incontinence yoga pilates respiratory training
using pet-ct to target and validate low-frequency tms as treatment for tinnitus

Conditions: Tinnitus

Summary: one out of every five people experience tinnitus (a buzzing, ringing, or roaring sound in the ear) ranging from mild to severe impairment. to date there is no effective therapy that seems to help the tinnitus sufferer. the purpose of this study is to develop a therapy using a technique called repetitive transcranial magnetic stimulation (rtms) to hopefully alleviate or reduce the symptoms of tinnitus. this research is being conducted at the university of arkansas for medical sciences (uams). up to twenty (20) right handed subjects, either males or females, 19-65 years of age, with tinnitus that is severe enough for those persons to seek medical attention will have been seen as patients in the uams hearing and balance center, where routine testing includes a physical exam, hearing tests, evaluation of middle ear status, and an mri scan (a machine that acquires visual images of the brain). a diagnosis of tinnitus will be established after ruling out all other possible causes of the tinnitus.

subjects will be up to 20 right-handed patients (men and women), 19-65 years of age, with debilitating unilateral or bilateral tinnitus. all subjects must report experiencing the presence of their phantom auditory perception for at least 6 months and have a tinnitus handicap questionnaire (thq) score \>30. subjects will be recruited from the otolaryngology clinic at uams, where routine testing includes a physical exam; pure tone audiometry; and evaluation of middle ear status using tympanometry, stapedius reflex tests, and otoscopy. patients will undergo a gadolinium-contrast mri of the head to rule out acoustic neuroma or any other central nervous system pathology. all subjects will be thoroughly informed of the risks associated with the procedures in this study, as described in the hazards to subjects section, and written informed consent will be obtained. subjects will be recruited for this study without regard to race or ethnicity.

Eligibility criteria:
inclusion criteria: * right-handed subjects * 19-65 years of age * debilitating unilaterial or bilateral tinnitus * experiencing the presence of phantom auditory preception for \>6 months * tinnitus handicap questionnaire score of \>30 exclusion criteria: * significant neurological disease * acoustic neuromas or glomus tumors * active meniere's disease * profound hearing loss * non english speaking * personal or family history of epilepsy * personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological or psychiatric disorders, metal implants in the head or neck, a pacemaker, pregnancy, migraines, * medications that lower seizure threshold and are contraindicated * individuals who have been taking certain medications * claustrophobia * patients who do not exhibit significant cortical asymmetries on pet

Keywords: tinnitus tms transcranial magnetic stimulation
reduction of systemic inflammation after ischemic stroke by intravenous dnase administration (rescind)

Conditions: Ischemic Stroke; Inflammatory Response

Summary: the goal of this (monocentric, randomised, placebo-controlled single-blinded; phase 2) clinical trial is to test the hypothesis that dnase 1 administration leads to a reduction in systemic immune response measured in patients after acute ischaemic stroke compared to control treatment. participants will receive intravenous dnase 1 (500 µg/kg) or placebo (nacl 0.9%) twice within 24±6 hours after symptom onset (last seen well). blood samples will be taken at baseline, day 1 and 3. personal visits will occur on baseline, day 1, 3 and discharge date. a telephone interview will be conducted on day 30±3.


Eligibility criteria:
inclusion criteria: * patients with suspected acute ischemic stroke with symptom onset (last-seen-well) until investigational drug application of less than 12 hours. * consent to participate in the study. * age ≥ 18 years. * nihss ≥10 at admission. exclusion criteria: * presence of any of the following conditions: sinus or cerebral venous thrombosis, intracerebral haemorrhage, subarachnoid haemorrhage on qualified imaging (cct with ct-a or mri with mr-a). however, petechial haemorrhagic transformations of the index infarct and cerebral microhaemorrhages may be included. * active malignant tumour disease in the last 6 months. * current known immunosuppression due to immunomodulatory medication with immunosuppressive dose or underlying immunosuppressive disease (e.g. hiv). * acute fulminant infectious disease in the last 7 days (fever \> 38.5°c or suspected by the investigator). * breastfeeding or pregnant woman, women of childbearing age without known use of contraceptives with positive urine or serum beta-human choriogonadotropin test. * ischemic stroke or myocardial infarction in the previous 30 days. * surgery in the previous 30 days, except minor dermatological or gynaecological surgery without anaesthesia and wound healing disorders and patients with thrombectomy. * estimated or known weight \> 100 kg. * known allergies or intolerance to dornase alfa (pulmozyme) or recombinant protein products derived from chinese hamster ovary cells. * thrombocytopenia, leukocyte count \<1500/μl. * known participation in another clinical trial investigating a drug and/or medical product in the last 7 days before study inclusion. * severe renal insufficiency with gfr≤29 ml/min/ 1.73m³ and/or renal insufficiency requiring dialysis.
to observe the clinical efficacy of traditional chinese medicine compound(weipi formula ) in the treatment of epigastric stuffiness syndrome

Conditions: Functional Dyspepsia(FD) Was Studied

Summary: the purpose of this clinical trial is to evaluate the efficacy of the herbal drug weipi formula in treating functional dyspepsia (fd) in adults. it will also assess the safety of weipi formula. the main questions the study aims to answer are: does weipi formula reduce participants' tcm syndrome scores? what medical issues might participants experience while taking weipi formula? researchers will compare weipi formula with a placebo (an identical-looking substance without active drugs) to determine whether weipi formula is effective in treating functional dyspepsia. participant procedures participants will: take weipi formula or the placebo daily for 2 weeks. visit the clinic once every week for examinations and tests. record their symptoms and undergo measurements (e.g., pepsin levels).


Eligibility criteria:
inclusion criteria: * ① meet the diagnostic criteria for epigastric fullness (pi-man) in traditional chinese medicine (tcm); * meet the western diagnostic criteria for functional dyspepsia (fd), specifically postprandial distress syndrome (pds) subtype, or meet both pds and epigastric pain syndrome (eps) subtypes but with pds as the dominant presentation; * age 18-80 years; * willing to sign the informed consent form. exclusion criteria: * ① gastroscopy findings: benign or malignant digestive diseases (e.g., peptic ulcer, gastric cancer); * severe organic diseases of the liver, gallbladder, spleen, or pancreas; * severe organic diseases in other organ systems; * pregnant or lactating women; ⑤ patients with psychiatric disorders causing similar symptoms (e.g., schizophrenia, anxiety disorder, major depressive disorder); ⑥ regular use (≥3 months) of nsaids and/or selective cox-2 inhibitors; ⑦ potassium supplements taken within 2 weeks prior to enrollment.
study of the preventable passage of patients over 75 years of age to the emergency room of the chru of nancy

Conditions: Emergencies Elderly

Summary: the adult emergency service of the nancy chru welcomes an average of 135 visits per day. approximately 18% are patients over 75 years old, among them 45% go home at the end of their care. the mobile geriatric liaison team intervenes with these patients at the request of the emergency doctors before they return home in order to identify their fragility and implement appropriate measures. we wish to know the characteristics of these avoidable passages in order to propose preventive measures upstream of these passages. to do this, we need to know the characteristics of those patients with an avoidable passage.


Eligibility criteria:
inclusion criteria: * age\>=75 years old * admitted at emergency room between first april 2019 and 30 september 2019 * outpatients exclusion criteria: * inpatients * discharged patients * patients discharged against medical advice * patients brought by police
is prolonged period of prone position effective and safe in mechanically ventilated patients with sars-cov-2?

Conditions: COVID-19 Acute Respiratory Distress Syndrome

Summary: the aim of the study is to assess safety and efficacy of prone position ventilation beyond the usual 16 hrs in patients with sars-cov-2


Eligibility criteria:
inclusion criteria: * - american society of anesthesiologists (asa) physical status ii- iii. * sex (male and females). * age 18 -80 years. * sever adult respiratory distress (ards) (defined as a pao2:fio2 ratio of \<150 mm hg, with a fraction of inspired oxygen (fio2) of ≥0.6, a positive end expiratory pressure (peep) of ≥5 cmh2o, and a tidal volume of 6 ml/kg of predicted body weight * mechanical ventilation for less than 36 hours exclusion criteria: * - contraindication for prone positioning * increased intracranial tension. * face trauma or surgery. * recent deep venous thrombosis * unstable spine, femur, or pelvic fractures * mean arterial pressure \< 65 mm hg * pregnant women * pneumothorax * prone positioning before inclusion * those returned to supine position before completing the session time
a post marketing surveillance study of equfina tablet 50 milligram (mg)

Conditions: Parkinson Disease

Summary: the purpose of this study is to describe the following in relation to the safety of equfina tablet 50 mg in the post marketing setting: 1. serious adverse events (saes) and adverse drug reactions (adrs) 2. unexpected adverse events (aes) and adrs not reflected in the precautions for use 3. known adrs 4. non-serious adrs 5. other safety and efficacy related information.


Eligibility criteria:
inclusion criteria: 1. participants with idiopathic parkinson's disease experiencing end of dose motor fluctuations who are receiving equfina tablet 50 mg as adjunctive treatment to levodopa-containing products 2. participants who have given their consent to study participation about the use of personal data and medical data exclusion criteria: 1. participants taking over monoamine oxidase (mao) inhibitors (example, selegiline hydrochloric acid \[hcl\], rasagiline mesylate) 2. participants taking opioid drugs (example, pethidine hcl containing drugs, tramadol hcl containing products or tapentadol hcl) 3. participants taking serotonergic drugs (example, tricyclic antidepressants, tetracyclic antidepressants, selective serotonin reuptake inhibitor, serotonin-noradrenaline reuptake inhibitors, selective noradrenaline reuptake inhibitor, noradrenergic and serotonergic antidepressant) or psychostimulant drugs (example, methylphenidate hcl, lisdexamfetamine dimesylate) 4. participants taking dextromethorphan 5. participants with severe hepatic impairment (child-pugh c) 6. participants with a history of hypersensitivity to any of the ingredients of equfina tablet 50 mg 7. pregnant women or women who may be pregnant

Keywords: equfina
atem (alvesco non-interventional study)

Conditions: Asthma; Allergy

Summary: the aim of the study is to evaluate the efficacy of alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. alvesco will be inhaled by a metered-dose inhaler. the study will provide further data on safety and tolerability of alvesco .


Eligibility criteria:
main inclusion criteria: * asthma with or without allergic components main exclusion criteria: * hypersensitive to compounds of alvesco * other criteria as defined in the summary of product characteristics, chapter 4.3

Keywords: asthma allergy ciclesonide alvesco inhaled steroids